BR112022018396A2 - Método de tratamento ou prevenção para insuficiência cardíaca crônica - Google Patents
Método de tratamento ou prevenção para insuficiência cardíaca crônicaInfo
- Publication number
- BR112022018396A2 BR112022018396A2 BR112022018396A BR112022018396A BR112022018396A2 BR 112022018396 A2 BR112022018396 A2 BR 112022018396A2 BR 112022018396 A BR112022018396 A BR 112022018396A BR 112022018396 A BR112022018396 A BR 112022018396A BR 112022018396 A2 BR112022018396 A2 BR 112022018396A2
- Authority
- BR
- Brazil
- Prior art keywords
- heart failure
- chronic heart
- prevention
- treatment
- treating
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4816—Wall or shell material
- A61K9/4825—Proteins, e.g. gelatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Cardiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Heart & Thoracic Surgery (AREA)
- Hospice & Palliative Care (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2020048798 | 2020-03-19 | ||
| PCT/JP2021/011003 WO2021187548A1 (ja) | 2020-03-19 | 2021-03-18 | 慢性心不全の治療又は予防方法 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112022018396A2 true BR112022018396A2 (pt) | 2022-11-08 |
Family
ID=77770987
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112022018396A BR112022018396A2 (pt) | 2020-03-19 | 2021-03-18 | Método de tratamento ou prevenção para insuficiência cardíaca crônica |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20230321044A1 (https=) |
| EP (1) | EP4122495A4 (https=) |
| JP (2) | JPWO2021187548A1 (https=) |
| KR (1) | KR20220156574A (https=) |
| CN (1) | CN115209919B (https=) |
| AU (1) | AU2021237149A1 (https=) |
| BR (1) | BR112022018396A2 (https=) |
| CA (1) | CA3175131A1 (https=) |
| MX (1) | MX2022011490A (https=) |
| WO (1) | WO2021187548A1 (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2020343585B2 (en) * | 2019-09-04 | 2026-02-05 | Shionogi & Co., Ltd. | Chronic kidney disease treatment or prevention method |
| MX2022002683A (es) * | 2019-09-04 | 2022-04-07 | Japan Tobacco Inc | Metodo terapeutico o profilactico para diabetes usando medicamentos combinados. |
| WO2023210634A1 (ja) * | 2022-04-28 | 2023-11-02 | 国立大学法人東海国立大学機構 | 拡張障害を伴う心不全の治療用医薬組成物 |
| WO2025249555A1 (en) * | 2024-05-31 | 2025-12-04 | Japan Tobacco Inc. | Method for treating or preventing hypertrophic cardiomyopathy |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW200735880A (en) * | 2006-01-27 | 2007-10-01 | Sankyo Co | Medicinal compositions for preventing or treating heart failure |
| AR087701A1 (es) * | 2011-08-31 | 2014-04-09 | Japan Tobacco Inc | Derivados de pirazol con actividad inhibidora de sglt1 |
| CN110066302B (zh) * | 2018-01-23 | 2022-12-27 | 广东东阳光药业有限公司 | 吡喃葡萄糖基衍生物及其用途 |
| TWI805699B (zh) * | 2018-03-01 | 2023-06-21 | 日商日本煙草產業股份有限公司 | 甲基內醯胺環化合物及其用途 |
| MX2020010433A (es) * | 2018-04-04 | 2020-10-28 | Japan Tobacco Inc | Compuestos de pirazol sustituidos con heteroarilo y uso farmaceutico de los mismos. |
| MX2022002683A (es) * | 2019-09-04 | 2022-04-07 | Japan Tobacco Inc | Metodo terapeutico o profilactico para diabetes usando medicamentos combinados. |
-
2021
- 2021-03-18 EP EP21772065.5A patent/EP4122495A4/en active Pending
- 2021-03-18 JP JP2022508425A patent/JPWO2021187548A1/ja active Pending
- 2021-03-18 WO PCT/JP2021/011003 patent/WO2021187548A1/ja not_active Ceased
- 2021-03-18 MX MX2022011490A patent/MX2022011490A/es unknown
- 2021-03-18 BR BR112022018396A patent/BR112022018396A2/pt not_active Application Discontinuation
- 2021-03-18 CA CA3175131A patent/CA3175131A1/en active Pending
- 2021-03-18 AU AU2021237149A patent/AU2021237149A1/en active Pending
- 2021-03-18 US US17/796,606 patent/US20230321044A1/en active Pending
- 2021-03-18 KR KR1020227035794A patent/KR20220156574A/ko active Pending
- 2021-03-18 CN CN202180021810.3A patent/CN115209919B/zh active Active
-
2026
- 2026-01-13 JP JP2026003199A patent/JP2026050471A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| KR20220156574A (ko) | 2022-11-25 |
| EP4122495A1 (en) | 2023-01-25 |
| EP4122495A4 (en) | 2024-03-27 |
| CN115209919A (zh) | 2022-10-18 |
| CN115209919B (zh) | 2024-12-31 |
| WO2021187548A1 (ja) | 2021-09-23 |
| CA3175131A1 (en) | 2021-09-23 |
| MX2022011490A (es) | 2022-10-07 |
| US20230321044A1 (en) | 2023-10-12 |
| AU2021237149A1 (en) | 2022-10-06 |
| JP2026050471A (ja) | 2026-03-19 |
| JPWO2021187548A1 (https=) | 2021-09-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112022018396A2 (pt) | Método de tratamento ou prevenção para insuficiência cardíaca crônica | |
| BR112019008431A2 (pt) | aplicação de (s)-norcetamina e sal da mesma como fármaco | |
| BR112021017350A2 (pt) | Combinação de conjugado de anticorpo-derivado de pirrolobenzodiazepina e inibidor de parp | |
| PH12021552872A1 (en) | Compounds and methods for the treatment of covid-19 | |
| BR112020017090A8 (pt) | Imunoterapias relacionadas com microbioma | |
| BR112022005896A2 (pt) | Inibidores da mek para o tratamento de infecções causadas por hantavírus | |
| CO2020013600A2 (es) | Tratamiento de la hidradenitis supurativa mediante el uso de inhibidores de jak | |
| CL2023001351A1 (es) | Métodos de tratamiento de la insuficiencia cardíaca mediante la administración de omecamtiv mecarbil. | |
| BR112018002046A2 (pt) | métodos de tratamento da síndrome de lennox-gastaut usando fenfluramina | |
| BR112023001143A2 (pt) | Conjugado, composto, composição farmacêutica, métodos para tratar uma doença e reduzir o nível de uma proteína brm alvo em um indivíduo | |
| BR112023001792A2 (pt) | Combinações para o tratamento de câncer | |
| BR112023021131A2 (pt) | Tratamento de tremor essencial | |
| AR110800A1 (es) | MÉTODOS PARA AUMENTAR EN PLASMA SANGUÍNEO LA 2-DESOXIURIDINA (dUrd) Y LA INHIBICIÓN DE LA TIMIDILATO SINTASA | |
| BR112023026992A2 (pt) | Medicamento para o tratamento e/ou prevenção do câncer, agentes que aumentam a eficácia do medicamento em uma composição farmacêutica e método para tratar e/ou prevenir o câncer | |
| BR112022018948A2 (pt) | Métodos de tratamento de lesão pulmonar com inibidores de cgrp | |
| BR112022015800A2 (pt) | Tratamento de colangite biliar primária com elafibranor | |
| BR112021026170A2 (pt) | Composição farmacêutica para tratamento de tumor?? | |
| BR112019005456A2 (pt) | composição farmacêutica e método para tratamento de esteatose hepática não alcoólica | |
| BR112015026631A2 (pt) | compostos ou sais farmaceuticamente aceitáveis dos mesmos e respectivos usos, composição farmacêutica e método para prevenir ou tratar diabetes melito em mamífero | |
| BR112022019338A2 (pt) | Tratamento preventivo de enxaqueca | |
| BR112022008223A2 (pt) | Métodos de tratamento e/ou prevenção de eventos cardiovasculares adversos maiores (ecam) com uma combinação de um inibidor do bromodomínio bet e um inibidor da proteína de transporte de glicose dependente de sódio 2 | |
| BR112019008698A2 (pt) | método para tratar câncer num sujeito que precisa do mesmo e composição farmacêutica | |
| BR112018072298A2 (pt) | tratamento de infecções pelo vírus da zika usando inibidores da alfa-glicosidase | |
| CO2025006782A2 (es) | Composición farmacéutica para la prevención o tratamiento contra úlcera péptica relacionada a fármacos, que comprende zastaprazán o una sal farmacéuticamente aceptable del mismo | |
| BR112022018707A2 (pt) | Composição farmacêutica, composição alimentícia funcional saudável e uso de ciclo-hispro ou um sal farmaceuticamente aceitável do mesmo |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B11A | Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing | ||
| B11N | Dismissal: publication cancelled [chapter 11.14 patent gazette] |
Free format text: ANULADA A PUBLICACAO CODIGO 11.1 NA RPI NO 2777 DE 26/03/2024 POR TER SIDO INDEVIDA. |